A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 4, 2008, Pages 1131-1138

  Cheng, Steven C ^a   Young, Daniel O ^a   Huang, Yihuang ^a   Delmez, James A ^a   Coyne, Daniel W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHELATING AGENT; NICOTINAMIDE; PHOSPHORUS; SODIUM PHOSPHATE COTRANSPORTER; VITAMIN B COMPLEX; VITAMIN D;

ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; HUMAN; HYPERPHOSPHATEMIA; KIDNEY DISEASE; MALE; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; BIOLOGICAL MARKERS; CHELATING AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DOWN-REGULATION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERPHOSPHATEMIA; KIDNEY DISEASES; MALE; MIDDLE AGED; NIACINAMIDE; PHOSPHORUS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS; TREATMENT OUTCOME; VITAMIN B COMPLEX; VITAMIN D; WASHINGTON;

EID: 49149098973     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04211007     Document Type: Article

References (30)

1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium-phosphorus product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
2. Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 35: 1226-1237, 2000
3. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[Suppl 3]: S1-S201. 2003
4. O'Brien T, Silverberg J, Nguyen T: Nicotinic acid-induced toxicity associated with cytopenia and decreased level of thyroxin-binding globulin. Mayo Clin Proc 67: 465-468, 1992
5. Delanaye P, Weekers L, Krzesinski J: Diarrhea induced by high doses of nicotinamide in dialysis patients. Kidney Int 69:1914,2006
6. Berndt TJ, Pfeifer J, Knox F, Kempson SA, Dousa TP: Nicotinamide restores phosphaturic effect of PTH and calcitonin in phosphate deprivation. Am J Physiol 242: F447-F452, 1982
7. Kempson SA, Colon-Otero G, Ou SY, Turner ST, Dousa TP: Possible role of nicotinamide adenine dinucleotide as an intracellular regulator of renal transport of phosphate in the rat. J Clin Invest 67: 1347-1360, 1981
8. Eto N, Miyata Y, Ohno H, Yamashita T: Nicotinamide prevents the development of hyperphosphatemia by suppressing intestinal sodium-dependent phosphate transporter in rats with a denin-induced renal failure. Nephrol Dial Transplant 20: 1378-1384, 2005
9. Katai K, Tanaka H, Tatsumi S, Fukunaga Y, Genjida K, Morita K, Kuboyama N, Suzuki T, Akiba T, Miyamoto, K, Takeda E: Nicotinamide inhibits sodium dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 14: 1195-1201, 1999
10. Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada N, Ebihara I, Koide H: Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 65: 1099-1104, 2004
11. Moher D, Schulz K, Altman D, CONSORT Group (Consolidated Standards of Reporting Trials): The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 134: 657-662, 2001
12. Eisenbarth G: Type 1 diabetes: A chronic autoimmune disease. N Engl J Med 314: 1360 -1368, 1986
13. Su C, Liu D, Kao S, Chen H: Nicotinamide abrogates acute lung injury caused by ischaemia/reperfusion. Eur Respir J 30:199-204,2007
14. Fukuzawa M, Satoh J, Muto G, Muto Y, Nishimura S, Miyaguchi S, Qiang XL, Toyota T: Inhibitory effect of nicotinamide on in vitro and in vivo production of tumor necrosis factor alpha. Immunol Lett 59: 7-11, 1997
15. Andersen HU, Jørgensen KH, Egeberg J, Mandrup-Poulsen T, Nerup J: Nicotinamide prevents interleukin-1 effects on accumulated insulin release and nitric oxide production in rat islets of Langerhans. Diabetes 43: 770-777, 1994
16. Horvath E, Szabo C: Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: An update. Drug New Prospect 20: 171-181, 2007
17. Block G, Klassen P, Lazarus J, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218,2004
18. Kalantar-Zadeh K, Kuwae N, Regidor D, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771-780, 2006
19. Saleh FN, Schirmer H, Sundsfjord J, Jorde R: Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 24: 2054-2060,2003
20. DeBoer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM: The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol 13: 2762-2769, 2002
21. Shalhoub V, Shatzen E, Henley C, Boedigheimer M, McNinch J, Manoukian R, Damore M, Fitzpatrick D, Haas K, Twomey B, Kiaei P, Ward S, Lacey DL, Martin D: Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols. Calcif Tissue Int 79: 431-442, 2006
22. Sampathkumar K, Selvam M, Sooraj YS, Gowthaman S, Ajeshkumar RN: Extended release nicotinic acid: A novel oral agent for phosphate control. Int Urol Nephrol 38: 171-174, 2006
23. Altschul R, Hoffer A, Stephen J: Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 54: 558-559, 1955
24. Carlson L: Nicotinic acid: The broad spectrum lipid drug. A 50th anniversary review. J Intern Med 258: 94-114, 2005
25. Lorenzen A, Stannck C, Lang H, Andrianov V, Kalvinsh I, Schwabe U: Characterization of a G protein-coupled receptor for nicotinic acid. Mol Pharmacol 59: 349-357, 2001
26. Wise A, Ford S, Fraser N, Barnes AA, Elshourbagy N, Eilert M, Ignar DM, Murdock PR, Steplewski K, Green A, Brown AJ, Dowell SJ, Szekeres PG, Hassall DG, Marshall FH, Wilson S, Pike NB: Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 278:9869-9874,2003
27. Yamada K, Fujimoto S, Tokura T, Fukudome K, Ochiai H, Komatsu H, Sato Y, Hara S, Eto T: Effects of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. Ren Fail 27: 361-365, 2005
28. Burke S, Dillon M, Hemken D, Rezabek MS, Balwit JM: Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv Ren Replace Ther 10: 133-145, 2003
29. Gale E, Bingley P, Emmett C, Collier T, European Nicotinamide Diabetes Intervention Trial (ENDIT) Group: European nicotinamide diabetes intervention trial (ENDIT): A randomized controlled trial of intervention before the onset of type 1 diabetes. Lancet 363: 925-931, 2004
30. Muller D, Mehling H, Otto B, Bergmann-Lips R, Luft F, Jordan J, Kettritz R: Niacin lowers serum phosphorus and increases HDL cholesterol in dialysis patients. Clin J Am Soc Nephrol 2: 1249-1254, 2007